249 related articles for article (PubMed ID: 34041562)
1. A multicenter comparison of [
Leuzy A; Pascoal TA; Strandberg O; Insel P; Smith R; Mattsson-Carlgren N; Benedet AL; Cho H; Lyoo CH; La Joie R; Rabinovici GD; Ossenkoppele R; Rosa-Neto P; Hansson O
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2295-2305. PubMed ID: 34041562
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in off-target binding using tau positron emission tomography.
Smith R; Strandberg O; Leuzy A; Betthauser TJ; Johnson SC; Pereira JB; Hansson O
Neuroimage Clin; 2021; 31():102708. PubMed ID: 34091353
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head comparison of tau positron emission tomography tracers [
Smith R; Schöll M; Leuzy A; Jögi J; Ohlsson T; Strandberg O; Hansson O
Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):342-354. PubMed ID: 31612245
[TBL] [Abstract][Full Text] [Related]
5. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
Ossenkoppele R; Rabinovici GD; Smith R; Cho H; Schöll M; Strandberg O; Palmqvist S; Mattsson N; Janelidze S; Santillo A; Ohlsson T; Jögi J; Tsai R; La Joie R; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; Choi JY; Ryu YH; Lyoo CH; Hansson O
JAMA; 2018 Sep; 320(11):1151-1162. PubMed ID: 30326496
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Binette AP; Vogel JW; Klein G; Borroni E; Tonietto M; Strandberg O; Mattsson-Carlgren N; Palmqvist S; Pontecorvo MJ; Iaccarino L; Stomrud E; Ossenkoppele R; Smith R; Hansson O;
JAMA Neurol; 2023 Jun; 80(6):614-623. PubMed ID: 37155176
[TBL] [Abstract][Full Text] [Related]
8. Compensating for choroid plexus based off-target signal in the hippocampus using
Pawlik D; Leuzy A; Strandberg O; Smith R
Neuroimage; 2020 Nov; 221():117193. PubMed ID: 32711062
[TBL] [Abstract][Full Text] [Related]
9. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
[TBL] [Abstract][Full Text] [Related]
10. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
11. Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden.
Bourgeat P; Krishnadas N; Doré V; Mulligan R; Tyrrell R; Bozinovski S; Huang K; Fripp J; Villemagne VL; Rowe CC
J Prev Alzheimers Dis; 2023; 10(2):251-258. PubMed ID: 36946452
[TBL] [Abstract][Full Text] [Related]
12. Regional [
Wolters EE; Ossenkoppele R; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Golla SSV; Windhorst AD; Boellaard R; van der Flier WM; Teunissen CE; Scheltens P; van Berckel BNM
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2866-2878. PubMed ID: 32291510
[TBL] [Abstract][Full Text] [Related]
13. Optimizing quantification of MK6240 tau PET in unimpaired older adults.
Harrison TM; Ward TJ; Murphy A; Baker SL; Dominguez PA; Koeppe R; Vemuri P; Lockhart SN; Jung Y; Harvey DJ; Lovato L; Toga AW; Masdeu J; Oh H; Gitelman DR; Aggarwal N; Snyder HM; Baker LD; DeCarli C; Jagust WJ; Landau SM;
Neuroimage; 2023 Jan; 265():119761. PubMed ID: 36455762
[TBL] [Abstract][Full Text] [Related]
14. Associations between quantitative [
Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
[TBL] [Abstract][Full Text] [Related]
15. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [
Tissot C; Servaes S; Lussier FZ; Ferrari-Souza JP; Therriault J; Ferreira PCL; Bezgin G; Bellaver B; Leffa DT; Mathotaarachchi SS; Chamoun M; Stevenson J; Rahmouni N; Kang MS; Pallen V; Margherita-Poltronetti N; Wang YT; Fernandez-Arias J; Benedet AL; Zimmer ER; Soucy JP; Tudorascu DL; Cohen AD; Sharp M; Gauthier S; Massarweh G; Lopresti B; Klunk WE; Baker SL; Villemagne VL; Rosa-Neto P; Pascoal TA
J Nucl Med; 2023 Mar; 64(3):452-459. PubMed ID: 36396455
[TBL] [Abstract][Full Text] [Related]
16. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
[TBL] [Abstract][Full Text] [Related]
17. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
18. Tracer-specific reference tissues selection improves detection of
Li Y; Ng YL; Paranjpe MD; Ge Q; Gu F; Li P; Yan S; Lu J; Wang X; Zhou Y;
Hum Brain Mapp; 2022 May; 43(7):2121-2133. PubMed ID: 35165964
[TBL] [Abstract][Full Text] [Related]
19. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA
J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
